Acute myeloid leukemia following a myeloproliferative neoplasm: clinical characteristics, genetic features and effects of therapy.

about

The Role of Reactive Oxygen Species in Myelofibrosis and Related Neoplasms Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia Kinase signaling and targeted therapy for primary myelofibrosis.

P2860

Q26779929-3813BD21-A2E4-49C4-B565-79E7EBA60D7D Q35217865-52C679E4-63EA-4CEB-A0E2-26FC274264B3 Q38775472-BD193570-8D78-4ED2-9A3D-43938131FFBB

P2860

Acute myeloid leukemia following a myeloproliferative neoplasm: clinical characteristics, genetic features and effects of therapy.

Item

http://www.wikidata.org/entity/Q38097735

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Acute myeloid leukemia followi ...... atures and effects of therapy.

@en

type

Item

label

Acute myeloid leukemia followi ...... atures and effects of therapy.

@en

prefLabel

Acute myeloid leukemia followi ...... atures and effects of therapy.

@en

P1476

Acute myeloid leukemia followi ...... atures and effects of therapy.

@en

P2093

Gabriela Soriano

http://www.w3.org/2001/XMLSchema#string

Mark L Heaney

http://www.w3.org/2001/XMLSchema#string

P2860

Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms

Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

Identification of an acquired JAK2 mutation in polycythemia vera.

Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.

Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome.

Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies.

DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms.

P2888

s11899-013-0154-5

P304

116-122

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11899-013-0154-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1020723262

http://www.w3.org/2001/XMLSchema#string

P698

23572311

http://www.w3.org/2001/XMLSchema#string

Acute myeloid leukemia following a myeloproliferative neoplasm: clinical characteristics, genetic features and effects of therapy.

about

P2860

P2860

Acute myeloid leukemia following a myeloproliferative neoplasm: clinical characteristics, genetic features and effects of therapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698